Literature DB >> 3864938

Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia-telangiectasia.

H V Vinters, R A Gatti, P Rakic.   

Abstract

An attempt was made to relate expression of neuronal abnormalities in ataxia-telangiectasia (AT) to the sequence of normal cellular events in the developing human cerebellum. Previous light and electron microscopic analyses indicate that the cerebellar cortex in humans develops during a protracted period that spans 8 fetal and 12 postnatal months. However, the Purkinje cells that comprise the most obvious lesion in the AT disorder are all generated before the end of the fourth fetal month. Correlative Golgi studies in human and [3H]thymidine labeling of DNA in dividing cerebellar cells in rhesus monkey demonstrate that after the last mitotic division Purkinje cells migrate to the cortical plate where they form a well-defined stratum below the embryonic molecular layer. Only thereafter do they begin to differentiate and develop their large dendritic tree. The dendrites grow in coordination and simultaneously with the genesis of parallel fibers in the molecular layer. The parallel fibers--the horizontal portion of granule cell axons--form between the fourth fetal and twelfth postnatal month in a well-defined inside-outside order, the earliest generated fibers being situated near the Purkinje cell layer and the last fibers generated lying closer to the pial surface. The four cases of AT examined in this study showed the usual neuropathological changes, which include a variable degree of Purkinje and granule cell loss. However, we emphasize here an abnormality of dendritic arborization and the presence of displaced Purkinje cells, which are situated in the middle and superficial strata of the molecular layer. Based on the sequence of histogenetic events, we argue that neither abnormal arborization nor aberrant position could be attained after parallel fibers of the deeper strata have been laid down and after Purkinje cells have formed their dendritic tree. Therefore, we suggest that the AT disorder in these cases must affect Purkinje cell differentiation or the interaction of these cells with parallel fibers during the first half of gestation, which is considerably earlier than any other recognized expression of the disorder. The subsequent degeneration of Purkinje cells is apparently not related to the aberrant position of the somas, since many Purkinje cells situated in normal position also die and there is no evidence that displaced cells degenerate at a slower or more rapid rate. The early expression of AT in the central nervous system provides new insight into possible pathogenesis and opens new avenues for research.

Entities:  

Mesh:

Year:  1985        PMID: 3864938

Source DB:  PubMed          Journal:  Kroc Found Ser        ISSN: 0361-0489


  13 in total

1.  SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs.

Authors:  Peiyee Lee; Nathan T Martin; Kotoka Nakamura; Soheila Azghadi; Mandana Amiri; Uri Ben-David; Susan Perlman; Richard A Gatti; Hailiang Hu; William E Lowry
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

2.  Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum.

Authors:  Liutao Du; Refik Kayali; Carmen Bertoni; Francesca Fike; Hailiang Hu; Patrick L Iversen; Richard A Gatti
Journal:  Hum Mol Genet       Date:  2011-05-16       Impact factor: 6.150

Review 3.  Ataxia-telangiectasia and related diseases.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

4.  A novel porcine model of ataxia telangiectasia reproduces neurological features and motor deficits of human disease.

Authors:  Rosanna Beraldi; Chun-Hung Chan; Christopher S Rogers; Attila D Kovács; David K Meyerholz; Constantin Trantzas; Allyn M Lambertz; Benjamin W Darbro; Krystal L Weber; Katherine A M White; Richard V Rheeden; Michael C Kruer; Brian A Dacken; Xiao-Jun Wang; Bryan T Davis; Judy A Rohret; Jason T Struzynski; Frank A Rohret; Jill M Weimer; David A Pearce
Journal:  Hum Mol Genet       Date:  2015-09-15       Impact factor: 6.150

5.  The postnatal development of cerebellar Purkinje cells in the Göttingen minipig estimated with a new stereological sampling technique--the vertical bar fractionator.

Authors:  Jacob Jelsing; Hans Jørgen G Gundersen; Rune Nielsen; Ralf Hemmingsen; Bente Pakkenberg
Journal:  J Anat       Date:  2006-09       Impact factor: 2.610

6.  Degeneration of neurons, synapses, and neuropil and glial activation in a murine Atm knockout model of ataxia-telangiectasia.

Authors:  R O Kuljis; Y Xu; M C Aguila; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.

Authors:  Liutao Du; Michael E Jung; Robert Damoiseaux; Gladys Completo; Francesca Fike; Jin-Mo Ku; Shareef Nahas; Cijing Piao; Hailiang Hu; Richard A Gatti
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

8.  Immunodeficiency, radiosensitivity, and the XCIND syndrome.

Authors:  Richard A Gatti; Elena Boder; Robert A Good
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Ataxia telangiectasia alters the ApoB and reelin pathway.

Authors:  Júlia Canet-Pons; Ralf Schubert; Ruth Pia Duecker; Roland Schrewe; Sandra Wölke; Matthias Kieslich; Martina Schnölzer; Andreas Chiocchetti; Georg Auburger; Stefan Zielen; Uwe Warnken
Journal:  Neurogenetics       Date:  2018-10-21       Impact factor: 2.660

10.  Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice.

Authors:  P R Borghesani; F W Alt; A Bottaro; L Davidson; S Aksoy; G A Rathbun; T M Roberts; W Swat; R A Segal; Y Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.